clinical danger (e.g. antibody formation from pregnant mare serum gonadotrophin; Creutzfeld-Jacob disease from human A randomized, controlled, double-blind, double-dummy, pituitary gonadotrophin) so, as recombinant technology phase III clinical trial was conducted in 84 women to evolved, the logic of increasing both a compound's purity and compare the efficacy of a s.c. injection of 250 µg recombinsafety could not be ignored. Such a uniform, specific product ant human chorionic gonadotrophin (rHCG; Ovidrel ® ) to would mean that drug production would no longer be dependent an i.m. injection of 5000 IU urinary HCG (uHCG; Profasi ® ) on the vagaries of urine collection and hormone extraction, in inducing folliculogenesis, resumption of oocyte meiosis allowing commercial production to be adjusted according to and luteinization after ovulation induction with recombinmarket requirements. In addition all urinary contaminants ant follicle stimulating hormone (Gonal-F ® ). The study would also be removed. Furthermore this would allow the safe primary endpoint was comparison of the number of oocytes s.c. administration of a compound with less batch-to-batch retrieved per patient receiving either compound. Secondary variation than has been demonstrated for urinary menopausal comparisons included the number of oocytes retrieved per gonadotrophin preparations (Rodgers et al., 1995) and thus follicles aspirated; the number of mature oocytes; normally potentially improve biological efficiency. These premises have fertilized oocytes; and cleaved embryos. There were no been extensively reviewed (Fauser, 1998 ; Loumaye et al., statistically significant differences between groups for the 1998; Prevost, 1998; Daya and Gunby, 1999) . primary endpoint (mean ⍨ SD oocytes retrieved 10.8 ⍨ Recombinant HCG (rHCG) has been manufactured by 4.5 for rHCG versus 10.3 ⍨ 5.1 for uHCG) or each of the transfecting non-human cell lines (Chinese hamster ovary secondary endpoints except for increased concentrations cells) with genetic material capable of replicating identical of progesterone 6-7 days after rHCG administration (353.2 amino acid sequences to the human compound and developed ⍨ 215.1 versus 234.1 ⍨ 129.4 nmol/l; P < 0.004) and for as a pharmaceutical product named Ovidrel ® . The clinical uses HCG during the luteal phase following rHCG (P < 0.02).
of HCG are based on its molecular similarity to LH where the There were also no significant side-effects for either drug.
first 114 amino acids of each compound share 80% homology.
Since the confidence intervals for the difference of the
The structural similarity of both compounds is further functionnumber of oocytes retrieved between the two treatment ally reflected by the fact that they bind to the same hormone groups were within the bounds defined by the multi-trial receptor (Pierce and Parson, 1981) . protocol equivalence between rHCG and uHCG could be Pre-clinical studies with Ovidrel ® in monkeys and rats have declared.
demonstrated that it is pharmacologically safe, well tolerated Key words: assisted reproduction treatment/ovulation inducover a large dose range and has no intrinsic toxicity. Similarly, tion/recombinant HCG/recombinant FSH/urinary HCG in mice, rHCG triggered germinal vesicle breakdown and extrusion of the first polar body and induced a dramatic increase in progesterone production (Smitz et al., 1998) .
Introduction
In limited unpublished clinical studies the linearity of the pharmacokinetics of Ovidrel ® after a single administration of The first preparations of human chorionic gonadotrophin (HCG) were investigated in the late 1930s (Lunenfeld and increasing doses was comparable to that of uHCG over a 500-20 000 IU dose range and the terminal half-life was estimated Insler, 1999). Subsequent studies and improved preparation of HCG from the urine of pregnant women (uHCG), where its as~30 h. A dose of 250 µg Ovidrel ® was also established to be equivalent to 5000 IU Profasi ® as an ovulatory stimulus in abundance allowed ease of extraction, meant that for almost 40 years it has been the sole hormonal preparation commercially monkeys (information provided by Ares-Serono International SA). marketed for induction of ovulation in anovulatory women. For the last two decades women undergoing assisted reproductive
The object of this study was to assess the safety and efficacy 
Materials and methods
followed by an ultrasound scan around day 42. The study was a randomized, controlled, double-blind, double-dummy, Study endpoints phase III clinical trial planned by the manufacturer to include a
The primary endpoint of the study was comparison of the total minimum of 80 women undergoing IVF or intracytoplasmic sperm number of oocytes retrieved per patient who received either rHCG injection (ICSI) and embryo transfer as part of a large, multi-trial or uHCG and to show equivalence between the two products. For clinical development of rHCG (Ovidrel). Participants were assessed adherence to the multi-trial protocol, equivalence had been prefor eligibility according to defined criteria. This included informed defined as falling within a clinically acceptable range of Ϯ 3 oocytes. couple consent, demographic information, medical and gynaecological This value had been established from the number of oocytes retrieved histories with physical examination combined with routine haematoin a similar patient population to that enrolled in this study and was logy, biochemistry and endocrine screening (including LH, FSH, calculated to give statistical power with the number of patients prolactin, oestradiol, progesterone and testosterone). Hormone anabeing studied. lyses were done using the ACS180 automated chemiluminescent Secondary comparisons included the number of patients with at immunoassay system (Bayer Diagnostics, 5 Thomas Hold Drive, least one oocyte retrieved; the number of oocytes retrieved per number North Ryde, NSW 2113, Australia). The male partner was assessed of follicles aspirated; the number of mature oocytes (i.e. metaphase I by semen analysis.
plus metaphase II); the number of normally fertilized oocytes; Patients were excluded if they had: (i) any clinically significant and the number of cleaved embryos (embryo utilization). Similarly systemic disease; (ii) a body mass index of Ͼ30 kgm 2 ; (iii) polycystic endocrine profiles and ultrasonic evaluation of endometrial thickness ovarian syndrome (PCOS); (iv) a previous history of severe ovarian during treatment was also compared. Total obstetric outcome was hyperstimulation syndrome (OHSS); (v) any medical condition which also evaluated but could not always be completed because some might interfere with the absorption, distribution, metabolism or patients still have embryos cryopreserved. The incidence and severity excretion of the medications; (vi) a prior or poor response to of adverse events (however minor), local tolerance to rHCG or uHCG gonadotrophin therapy or a previous history of intolerance to FSH, administration and the incidence of mild, moderate or severe OHSS gonadotrophin releasing hormone (GnRH) agonists or to HCG; (vii) in each group was also assessed by clinical, ultrasonographic and active substance abuse (including smokers consuming more than biochemical parameters. All data entry, compliance and analysis was 20 cigarettes/day); more than three previous assisted reproductive performed by contract statisticians (Datapharm Australia Pty Ltd, PO treatment attempts or any form of infertility treatment in the previous Box 220, Five Dock, NSW 2046, Australia). two menstrual cycles or (viii) a male partner with leukospermia or bacterial infection detected in a semen analysis within the last 3 months.
Results

Recruitment and patient distribution Treatment
Standard assisted reproductive treatment protocols were used for Ninety patients were enrolled into the study, 74 in Australia ovarian stimulation. Thus patients received 400 µg of intranasal and 16 in New Zealand. Of these, six withdrew prior to nafarelin (Synarel; Searle Pharmaceutical Products, Sydney, Australia) randomization (one for failure of treatment, four for risk of twice daily from the mid-luteal phase to achieve down-regulation OHSS and one due to a breakthrough LH surge) leaving 84 (oestradiol concentration ഛ180 pmol/l, progesterone Ͻ4.0 nmol/l, who were randomized and received HCG, 44 in the rHCG and LH Ͻ3.0 IU/l). This was confirmed by measurement of serum 40 in the uHCG groups.
concentrations of oestradiol LH and progesterone. If down-regulation Of those patients who met protocol requirements nine did could not be achieved after 10 days the patient was withdrawn from not proceed to embryo transfer, five in the rHCG group and the study. On commencing ovarian stimulation with recombinant four in the uHCG group. In the rHCG group one was because FSH (rFSH, Gonal-F ® ) the dose of nafarelin was reduced to 200 µg of failed fertilization, three due to the risk of OHSS and one twice daily.
Nafarelin and rFSH treatment (not required to remain at a fixed due to poor quality embryos which were unsuitable for either dose but required to be Ͻ450 IU/day) were administered until the transfer or cryopreservation. In the uHCG group one woman criteria for induction of ovulation were met (largest follicle ജ18 mm was discontinued because of failed fertilization and three others diameter; presence of at least two other follicles with a mean diameter due to the risk of OHSS. None of the women at risk or any groups for any demographic characteristic assessed. The mean (Ϯ SD) age of women was 32 Ϯ 4 years, with a range of between the two treatment groups was 0.475, with a 90% confidence interval (CI) of -0.945, 1.895, and the least squares 21-38 years. Most (84.5%) were non-smokers. Their mean (Ϯ SD) weight and body mass index (BMI) were 63.2 Ϯ mean difference was 1.046 with a 90% CI of -0.382, 2.474. Since both CI were within the required range of Ϯ 3 the two 9.5 kg and 23.3 Ϯ 3.1 kg/m 2 respectively. treatments could be declared equivalent.
Infertility history
Secondary efficacy analysis The two treatment groups were similar for all gynaecological
In the secondary efficacy analysis there were no significant and obstetric parameters with the exception of the type of differences (Table I) between the two treatment groups in the infertility. Thus there was a higher percentage of patients with number of oocytes retrieved per number of follicles Ͼ10 mm primary infertility in the rHCG group (79.5%) than in the on the day of HCG (but prior to HCG administration), the uHCG group (57.5%), and a correspondingly higher percentage number of mature (metaphase, MI plus MII) oocytes retrieved, of patients with secondary fertility in the uHCG group, 42.5% the number of normally fertilized (2-pronucleate, PN) oocytes compared with 20.5% in the rHCG group (P ϭ 0.029). The per patient (after insemination or ICSI), or in the number of median duration of infertility for all women was 3 years, with cleaved embryos developing from fertilized oocytes or the male infertility being cited most commonly as the cause of number of women who had supernumerary embryos cryopreinfertility in both treatment groups (55.8% rHCG versus 51.1% served. All patients had at least one oocyte retrieved. While uHCG). Male factor infertility was given as the only cause of the implantation rate has been calculated for those patients infertility by 23 (52.3%) couples in the rHCG group and 18 where data was available it remains incomplete since some (45.0%) couples in the uHCG group. embryos still remain cryopreserved Ͼ12 months after closing Endocrinology and drug use the study. There were no differences between the treatment groups for Serum progesterone concentrations were assessed during any of the initial screening hormone concentrations (mean Ϯ the luteal phase (Table II) and in both groups concentrations SD, rHCG group versus uHCG group: FSH, 4.6 Ϯ 2.1 versus rose consistently. Although there were no significant differ-4.3 Ϯ 1.9 IU/l; LH, 4.6 Ϯ 2.5 versus 4.9 Ϯ 2.6 IU/l; ences between the peri-ovulatory period, a significant differtestosterone, 1.1 Ϯ 0.4 versus 1.2 Ϯ 0.5 nmol/l; oestradiol, ence became apparent 6-7 days after HCG with progesterone 338. 129.4 nmol/l) in the rHCG group. Serum HCG concentrations versus 13.2 Ϯ 6.8 ng/ml). Similarly there were no statistically were also assessed on the same days as progesterone. In both significant differences between treatment groups in either the groups the mean HCG concentration fell consistently during duration or total dosages of nafarelin and rFSH used. Thus the luteal phase (Table II) but statistically significant differences patients in the rHCG group were given a mean (Ϯ SD) total occurred at all time points (P Ͻ 0.05), mean concentrations dose of 14 627 Ϯ 2035 µg nafarelin for a mean period of 24 being greatest in the rHCG group. days down-regulation compared to the uHCG group of With respect to pregnancies, there was no statistically 15 370 Ϯ 2743 µg for a mean period of 25 days downsignificant difference between treatment groups in either the regulation, neither dose nor duration being significantly number of patients with biochemical pregnancies (HCG different. Comparing rFSH use, women in the rHCG group ജ25 IU/l), or the number of patients with clinical pregnancies received a total dose of 2141 Ϯ 725 IU (i.e. 28.5 ampoules (fetal sacs, with or without a fetal heart). Six patients (15.4%) ϫ75 IU) compared to 2067 Ϯ 910 IU (i.e. 27.6 ampoules in the rHCG group recorded clinical pregnancies and included ϫ75 IU) in the uHCG group during a mean period of 12 days in these was one set of triplets, making eight fetal hearts in ovarian stimulation in each group.
all. Seven patients (19.4%) in the uHCG group recorded clinical pregnancies, including one patient who had two fetal Study comparisons sacs but only one fetal heart, and one with one fetal sac, but Primary efficacy analysis no detectable heartbeat. Hence there was one patient (16.7%) The number of oocytes retrieved in the two groups was with a continuing multiple pregnancy (triplets) in the rHCG examined using an analysis of covariance model taking into group but no patient in the uHCG group with a multiple account the number of follicles Ͼ10 mm at the baseline pregnancy (not significant). There were no miscarriages in the ultrasound assessment together with the research unit (Australia rHCG group but four in the uHCG group, two of which have or New Zealand) and the couples' infertility type (primary or been mentioned above and two which miscarried after fetal secondary). All interaction effects (two-, three and four-way) heartbeats were detected by ultrasound. There were no extrawere tested and found to be non-significant and were dropped uterine pregnancies. from the model one by one, using a backwards stepwise Adverse events method. Infertility and the research unit effect were found to be non-significant and were dropped from the model. Thus, There were no clinically significant results for haematology, biochemistry or urine analysis and no clinically significant as shown in Table I , in the rHCG group the mean Ϯ SD number of oocytes retrieved was 10.8 Ϯ 4.5 whereas in the changes during the study. Adverse events were reviewed overall and were also classified for each patient according uHCG group it was 10.3 Ϯ 5.1, and the least square means Ϯ SEM, after adjusting for the baseline follicle count, were to the highest severity of any episode they experienced (Table III) . There was only one episode that was severe 11.0 Ϯ 0.6 and 10.0 Ϯ 0.6 respectively. The mean difference There were no significant differences between the two groups by analysis of variance. a Only possible to assess in those women having ICSI (n ϭ 30 and n ϭ 22 for rHCG and uHCG respectively). b Pregnancy data from cryopreserved embryos not possible to evaluate since embryos still remain in store. c All utilizable embryos but not fully evaluated since some embryos still remain cryopreserved. rHCG ϭ recombinant human chorionic gonadotrophin; uHCG ϭ urinary HCG. (i.m. injection site pain; uHCG group) and this resolved on the same day. All other events were considered mild or moderate. Local tolerance to injections was also recorded. injection method.
Discussion phase. However, whether this would allow a more favourable luteal environment for implantation will need further study. The onset of the spontaneous LH surge in women is relatively With respect to patient use, reported side-effects were minor abrupt with concentrations doubling within 2 h to between and generally related to the injection site (pain, inflammation 100 and 200 IU/l being sustained for 12-14 h over a mean or reaction) but a higher proportion of patients (42.5%) duration of 50 h (Hoff et al., 1983) . This mid-cycle surge, in experienced these reactions in the uHCG group (s.c. placebo) addition to follicular rupture (Espy, 1974) , promotes several compared with the use of rHCG (i.m. placebo; 20.5%). peri-ovulatory events including disruption of the oocyteThus rHCG appears also to show better patient acceptance. cumulus oophorous cell contact and induction of the resumption Hypersensitivity reactions are a documented complication of of the oocyte's meiotic maturation (Laurence et al., 1980) , urinary-derived gonadotrophin therapy and, in a case report, a cumulus oophorous mucinification, luteinization of the follicpatient allergic to uFSH was successfully treated with r-FSH ular granulosa cells (Brailly et al., 1981) and secretion of (Whitman-Elia et al., 1998) . progesterone.
To conclude, a s.c. injection of a 250 µg rHCG (Ovidrel ® ) These events are also induced by an injection of HCG has been shown to be equivalent to an i.m. injection of 5000 through exactly the same sequence, the only difference being IU uHCG (Profasi ® ) in inducing final follicular maturation, in the pharmacokinetic profile where the mean duration of the resumption of meiosis in oocytes and early luteinization in 'surge' after an i.m. injection of 5000 IU uHCG is longer than women undergoing ovulation induction with rFSH (Gonal-F ® ) for LH (~96 h) and maximum concentrations may be less prior to assisted reproductive treatment. The authors believe (Fischer et al., 1993) . Current practice is that ജ5000 IU uHCG that the births resulting from this study are the first reported is an acceptable ovulatory dose and that lesser concentrations after IVF and ICSI using this combination of recombinant can lead to reduced oocyte recovery and a lower fertilization gonadotrophins, confirming the prediction of Agrawal et al. rate in assisted reproductive treatments (Abdalla et al., 1987) .
(1997) in their case report of a single ongoing pregnancy. Duffy et al. (1996) have also demonstrated in monkeys that rHCG is equally efficacious as uHCG in stimulating thepregnancy rates. Of the only two significant differences between the treatment midcycle: A revelation. J. Clin. Endocrinol. Metab., 57, [792] [793] [794] [795] groups, both were secondary effects and offered potential Karamardian, L.M. and Grimes, P.A. (1992) 
